- Home
- WBX vs PRQR Comparison
WBX vs PRQR Comparison
Compare WBX & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBX
- PRQR
- Stock Information
- Founded
- WBX 2015
- PRQR 2012
- Country
- WBX Spain
- PRQR Netherlands
- Employees
- WBX N/A
- PRQR N/A
- Industry
- WBX Industrial Specialties
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- WBX Consumer Discretionary
- PRQR Health Care
- Exchange
- WBX Nasdaq
- PRQR Nasdaq
- Market Cap
- WBX 66.9M
- PRQR 232.8M
- IPO Year
- WBX N/A
- PRQR 2014
- Fundamental
- Price
- WBX $4.11
- PRQR $2.06
- Analyst Decision
- WBX Buy
- PRQR Strong Buy
- Analyst Count
- WBX 4
- PRQR 8
- Target Price
- WBX $10.50
- PRQR $8.88
- AVG Volume (30 Days)
- WBX 17.6K
- PRQR 368.1K
- Earning Date
- WBX 11-05-2025
- PRQR 11-06-2025
- Dividend Yield
- WBX N/A
- PRQR N/A
- EPS Growth
- WBX N/A
- PRQR N/A
- EPS
- WBX N/A
- PRQR N/A
- Revenue
- WBX $173,788,608.00
- PRQR $20,129,184.00
- Revenue This Year
- WBX N/A
- PRQR N/A
- Revenue Next Year
- WBX $46.25
- PRQR N/A
- P/E Ratio
- WBX N/A
- PRQR N/A
- Revenue Growth
- WBX N/A
- PRQR 8.65
- 52 Week Low
- WBX $3.69
- PRQR $1.07
- 52 Week High
- WBX $25.70
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- WBX 47.24
- PRQR 42.63
- Support Level
- WBX $3.94
- PRQR $1.91
- Resistance Level
- WBX $4.20
- PRQR $2.50
- Average True Range (ATR)
- WBX 0.19
- PRQR 0.16
- MACD
- WBX 0.02
- PRQR -0.04
- Stochastic Oscillator
- WBX 70.00
- PRQR 25.42
About WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.